Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Open Label Phase 2 Feasibility Study of BPX-04 Topical Minocycline Gel in Rosacea

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03050086
Recruitment Status : Completed
First Posted : February 10, 2017
Last Update Posted : January 31, 2019
Sponsor:
Information provided by (Responsible Party):
BioPharmX, Inc.

Brief Summary:
An open label feasibility study using BPX-04 topical minocycline gel in papulopustular rosacea.

Condition or disease Intervention/treatment Phase
Moderate to Severe Papulopustular Rosacea Drug: BPX-04 1% minocycline topical gel Drug: BPX-04 2% minocycline topical gel Drug: BPX-04 vehicle topical gel Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open Label Phase 2 Feasibility Study to Assess the Safety and Efficacy of BPX-04 Minocycline Topical Gel in Treatment of Moderate to Severe Papulopustular Rosacea (BPX-01-C05)
Actual Study Start Date : March 29, 2017
Actual Primary Completion Date : June 19, 2018
Actual Study Completion Date : June 19, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Rosacea

Arm Intervention/treatment
Experimental: BPX-04 1% Minocycline Topical Gel
once daily topical administration of 1% minocycline gel to the face
Drug: BPX-04 1% minocycline topical gel
once daily administration of topical minocycline gel to face

Experimental: BPX-04 2% Minocycline Topical Gel
once daily topical administration of 2% minocycline gel to the face
Drug: BPX-04 2% minocycline topical gel
once daily administration of topical minocycline gel to face

Placebo Comparator: BPX-01 Vehicle Topical Gel
once daily topical administration of vehicle gel to the face
Drug: BPX-04 vehicle topical gel
once daily administration of topical minocycline gel to face




Primary Outcome Measures :
  1. Investigator's Global Assessment [ Time Frame: 12 weeks ]
    papules, pustules and erythema


Secondary Outcome Measures :
  1. Lesion count [ Time Frame: 12 weeks ]
    papules and pustules



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or female subjects ≥18 years of age at the time of consent.
  2. Subjects do not have any medical conditions, other than rosacea, that in the opinion of the investigator, put the subject at unacceptable risk or could interfere with study assessments or integrity of the data.
  3. A clinical diagnosis of moderate to severe (Grade 3 or 4) facial rosacea (papulopustular (Subtype 2) or mixed erythematotelangiectatic (Subtype 1) and papulopustular (Subtype 2)) as determined by the Investigator's Global Assessment (IGA) at Visit 1/Screening.
  4. Female subjects of childbearing potential (including pre-puberty) are willing to use effective contraceptive method for at least 28 days before baseline (Day 0) and at least 28 days after the last study product administration or have a sterilized or same-sex partner for the duration of the study. Hormonal contraceptives must be on a stable dose for at least 12 weeks before baseline (Day 0). Subjects using low dose oral contraceptives must use a second form of birth control (e.g., barrier method such as condoms with spermicide).

    Note: Female subjects of non-childbearing potential are defined as follows:

    1. Female subjects who have had surgical sterilization (hysterectomy, bilateral oophorectomy, bilateral salpingectomy, or bilateral tubal ligation);
    2. Female subjects who have had a cessation of menses for at least 12 months and a follicle-stimulating hormone (FSH) test confirming non-childbearing potential (refer to the central laboratory reference range for menopausal women) or cessation of menses for at least 24 months without FSH levels confirmed;
  5. Female subjects of childbearing potential must have a negative urine pregnancy test at screening and baseline (Day 0).
  6. Treatment with hormonal therapy must be on a stable dose and frequency for at least 12 weeks before baseline (Day 0) and must remain stable throughout the study.
  7. Subjects who use make-up, facial moisturizers, creams, lotions, cleansers and/or sunscreens must have used the same product brands/types for a minimum period of 14 days prior to baseline (Day 0), must agree not to change brand/type or frequency of use throughout the study and must agree not to use make-up, facial moisturizers, creams, lotions, cleansers and/or sunscreens on the clinic visit days before the visit.
  8. Subjects must be capable of giving informed consent and the written informed consent must be obtained prior to any study-related procedures.

Exclusion Criteria:

  1. Have a history of skin disease, presence of skin condition or excessive facial hair the PI believes would interfere with the study
  2. Have moderate or severe rhinophyma, severe telangiectasia or plaque-like facial edema
  3. Have rosacea conglobata or fulminans, corticosteroid induced rosacea or facial erythrosis other than rosacea
  4. Have ocular rosacea of a severity that requires systemic treatment
  5. Have a history of any adverse reaction to minocycline or other tetracycline class antibiotic
  6. Have a clinically significant chemistry or hematology value at baseline or have an ALT or AST at screening that is greater than or equal to 2x normal
  7. Have conditions or factors that the PI believes may affect the response of the skin or the interpretation of the results
  8. Participated in any clinical study with exposure to any investigational treatment or product within the previous 30 days, or plan on concurrent participation in other studies
  9. Have used on the face an OTC topical medication for the treatment of rosacea within 4 weeks prior to baseline.
  10. Have used prescription topical (on the face) or oral antibiotics or corticosteroids within 4 weeks prior to baseline.
  11. Have had a facial procedure such as chemical peel, laser, microdermabrasion within 8 weeks prior to baseline
  12. Have received photodynamic therapy or phototherapy with blue or red light within 12 weeks prior to baseline
  13. Have used an oral retinoid within 6 months or a topical retinoid within 3 months prior to baseline
  14. Current drug or alcohol abuse
  15. Female subject who is breastfeeding, pregnant or who is planning a pregnancy during the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03050086


Locations
Layout table for location information
United States, California
Study Center
San Diego, California, United States, 92123
Sponsors and Collaborators
BioPharmX, Inc.
Investigators
Layout table for investigator information
Study Director: AnnaMarie Daniels BioPharmX, Inc.

Layout table for additonal information
Responsible Party: BioPharmX, Inc.
ClinicalTrials.gov Identifier: NCT03050086     History of Changes
Other Study ID Numbers: BPX-01-C05
First Posted: February 10, 2017    Key Record Dates
Last Update Posted: January 31, 2019
Last Verified: January 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Rosacea
Skin Diseases
Minocycline
Anti-Bacterial Agents
Anti-Infective Agents